The Opportunity CANADIAN GROWING FACILITIES AUSTRALIAN GROWING FACILITIES CBD PRODUCT AND BRAND DEVELOPMENT

Transcription

1 EXECUTIVE SUMMARY 2017

2 The Opportunity CANADIAN GROWING FACILITIES MYM has two production projects. both in Quebec - Laval and Weedon. Laval - Facility is currently under construction and is expected to be licensed by Q The facility is 10,000 sf and will be expanded to 26,000 sf. This license will enable MYM to manufacture its branded THC and CBD products across Canada and the United States. The Laval project is projected to produce sales of $20 million by 2019 with profit estimates of $11 million. MYM owns 51%. Weedon million sf greenhouse project has been approved by the City of Weedon and Health Canada. A license application has been submitted. The City of Weedon has purchased 329 acres of land for MYM to build on. This project will include a cannabis museum and a cannabis university for industry training. The Weedon project is projected to produce sales of $750 million by 2021 with profit estimates of $325 million. MYM owns 75% (increasing to 90% upon completion). AUSTRALIAN GROWING FACILITIES The Northern Rivers Project a 1.2 million sf greenhouse project which, upon completion, will be the largest cannabis greenhouse in Australia. The first crop is expected to be planted in the fourth quarter of At full scale, the new facility will have the capacity to support annual production that equates to an annual revenue potential of between C$800 million and C$1.1 billion. MYM owns 35%. CBD PRODUCT AND BRAND DEVELOPMENT MYM owns three CBD brands, HempMed, Joshua Tree and Dr. Furbaby. Joshua Tree and Dr. Furbaby brands will be available throughout Canada and the USA by the end of HempMed is a brand targeted at the dispensary market and has been growing rapidly at 200% per quarter. Online sales for HempMed have increased by 600% since March. HempMed and its 21 prodcuts is on track to do $2 million in sales this year. MYM owns 100%. Joshua Tree is targeted for the mainstream health market. Joshua Tree will be launched in the Q in Canada and the USA. Joshua Tree and its 28 products are projected to do over $4 million in sales next year. MYM owns 100%. Dr. Furbaby is our CBD line of products specifically created for pets. This is a rapidly growing market that is highly profitable and will be launched this year in Canada and the USA. Dr. Furbaby is projected to do over $300,000 in sales within the first year. MYM owns 100%.

3

4 Production Facilities The world is changing. People are looking for alternative treatments to their physical ailments and while regulation has been slow to change, 2018 is the year recreational use will become a reality. With change, new opportunities arise for those that are ready and willing to serve the demands of the marketplace. MYM Nutraceuticals has a detailed plan to serve this emerging marketplace. Our strategy will allow us to be successful navigating this new, heavily regulated market. MYM has launched a line of products that serve as everyday health and wellness for those looking for the health benefits of CBD products. This first phase of our business will generate cash flow and establish sales channels that will eventually aid in integrating new THC products that will be introduced in phase 2, when recreational cannabis is legalized. With Health Canada licensing scheduled to happen Q for the Laval project, MYM will be able to offer cannabis products from different strains to our customers. MYM plans immediate expansion of the facility to include a state of the art extraction department, allowing the company to capitalize on all the harvested trimmings and small cannabis flowers of the previous year and anything harvested going forward. With the ability to extract we will then launch our new THC product lines to our clients. To expand our product offering we will look to acquire an import/export license as well as build on relationships with other ACMPR companies to help us meet the growing demand nationally and abroad. The Company expects to start construction of the Weedon project in The first phase consists of three 100,000 sf greenhouses and will include a 100,000 sf warehouse for processing and storage. The remaining 12 greenhouses will be built out over the next 4 years. Having built a nationally and globally recognized brand and large scale production facilities, MYM will have the resources, high margins, and cash flow to continue expansion worldwide.

5 The Cannabis Market CANADA CANNABIS MARKET PROJECTIONS US CANNABIS MARKET PROJECTIONS $8 BILLION $25 BILLION $6 BILLION $20 BILLION $4 BILLION $15 BILLION $2 BILLION $10 BILLION $ $0 CURRENT LICENCED PRODUCERS RECREATIONAL VS MEDICAL USAGE QC NB PE BC 17 2 MB MEDICAL 37% ON 43 4 AB 4 SK RECREATIONAL 63%

6 Project Production Details WEEDON QUEBEC When Phase 1 is completed in 2018, CannaCanada will be one of Canada s largest medical cannabis producers. By full capacity (Phase 3 in 2020), we could be the most productive cannabis facility in the entire world by total output. The target for the initial 300,000 sf Phase 1 is to produce 27,000 to 30,000 kilograms per year for WEEDON QC GREENHOUSE PRODUCTION PHASE 1 PHASE 2 PHASE 3 PRODUCTION SIZE (SQ.FT) 300, ,000 1,500,000 LOW END - CROP/STRAIN (KG) HIGH END - CROP/STRAIN (KG) GROSS $8.5/G (LOW END) GROSS $8.5/G (HIGH END) 27,000 54, ,000 30,000 60, , ,500, ,000,000 1,147,500, ,000, ,000,000 1,275,000,000 Greenhouse operations have a smaller carbon footprint and lower operational costs. Greenhouse cannabis requires far fewer resources and is less expensive to produce than cannabis grown indoors. Greenhouse production uses the natural environment to fuel its growth and requires much less artificial, high-intensity lighting. Compared to indoor grown cannabis, sun grown plants typically require fewer soil amendments, fertilizers, pesticides, and fungicides. The Weedon project includes a 33,000 sf warehouse building that houses the research laboratory, extraction facility, processing area and vault storage.

7 The Weedon Project Phases

8 The Weedon Canna Centre Weedon plans to have the worlds largest, zero carbon foot print, Canna Centre. It will be home to an education centre that will be working with universities regarding botany degrees and vocational programs with certifications in cannabis plant and operations from seed to sale. It will also have an attached a R&D lab, a test facility, and a 2005 person auditorium for lectures. There will be a cannabis history museum and a health care clinic with twenty-two 1000 sf apartments for treatments. This plan will make Weedon the cannabis capital of Canada.

9 hot tub hot tub sauna The Canna Centre Aerial View new road AUDITORIUM 2005 PEOPLE TOTAL A B Chemin Ferry 1 2 CAFETERIA HALL D C parking '-0" 42'-0" MUSEUM STREET plantations in RESEARCH & DEV. 259 vip terrasse stair E trail terrasse 42'-0" ARCHIVE 14'-2 1 4" ramp down installations and plantations zone F 35'-0" 35'-0" 30'-0" TYP. paved path for firetrucks (min. 6') wetlands and plantations zone pa ramp down lounge zone trail new road pa pavilions and picnic tables zone seating zone parking 251 existing pond existing pond 250 exterior stage

10 Project Production Details LAVAL QUEBEC When Phase 1 is completed in 2018, Sublime Culture will be producing 1,000 kilograms of premium indoor medical cannabis annually. By full capacity (Phase 2 in 2019) it will be producing 2,800 kilograms annually. The Laval project will facilitate the production and distribution of cannabis products, including both Indica and Sativa Cannabis flowers (buds) for sale to our patients as well as high-end Co₂ extracted oils (concentrates) and products made from those oils. The 10,000 sf facility will produce 770 to 890 kilograms of cannabis flowers, enough to generate annual revenues estimated at $4.9 million for Phase 1. That figure increases with the revenue potential of an additional $14 million with Phase 2. An additional $2.5 million in extracts will be produced in this facility once Phase 2 is completed. With monthly operating expenses of $150,000 this will generate an annualized EBITDA of $6.5 to $7.5 million. The first stage is already underway and will be completed in late 2017 at a cost of $2.3 million. Production will begin in late 2017 with the first harvest completed by the end of Jan MYM will immediately start Phase 2 build-out of the existing building to a 26,000 sf fully integrated facility. This build-out, when completed, will generate revenues projected to hit $18 million by year 2 (capacity at 95%) and $25 million by year 3 (capacity at 98%). LAVAL QC PRODUCTION PHASE 1 PHASE 2 PRODUCTION SIZE (SQ.FT) 10,000 26,000 LOW END - CROP/STRAIN (KG) 700 2,500 HIGH END - CROP/STRAIN (KG) ,800 GROSS $8.5/G (LOW END) 5,950,000 21,250,000 GROSS $8.5/G (HIGH END) 8,500,000 23,800,000 SOUTH AMERICA Low cost licensing, build costs and labor makes S.A. very attractive for production for export. MYM is working on a production, extraction and export license. MYM believes the international trade of cannabis concentrates and products will be commonplace in the coming years. Columbia has a perfect climate, low wages, and light regulation, making it ideal for the production of oils and concentrates that MYM uses for its branded products.

11 CBD Production Details MYM offers a variety of CBD-infused supplements designed to enhance overall health and treat ailments such as; pain & inflammation, anxiety, diabetes, seizures, insomnia, Parkinson's and cardiovascular health. The big selling point for the surging popularity of CBD products has been that it is non euphoric, as it contains little or no THC. The rise of medical marijuana has also introduced CBD to the mainstream health and wellness market and MYM believes this sector will see massive growth over the next 10 years. Cannabis has been shown in both tissue culture and mice to be effective at inhibiting the growth of many cancers. CBD plays an important role in the anti-neoplastic (anti-cancer) effect. Cannabis is an antioxidant which has been shown to decrease the incidence of cancer. These factors will drive CBD sales as the population becomes more educated on the many benefits of CBD. Our CBD products have fantastic margins ranging from 100% to 500%. CANADA CBD SALES JOSHUA TREE ($) 800,000 2,800,000 5,600,000 HEMPMED ($) 1,200,000 2,400,000 3,600,000 DR. FURBABY ($) 150, ,000 1,320,000 TOTAL SALES ($) 2,150,000 5,800,000 10,520,000 US CBD SALES ,200,000 5,400,000 2,904,000 19,504, MJT MANUFACTURING JOSHUA TREE ($) 400,000 4,000,000 8,000,000 16,000,000 MJT Manufacturing Project the 5,000 sf production facility located in Toronto, Ontario is a GMP certified, state of the art extraction lab and production facility dedicated to industrial hemp processing (CBD). This high capacity production space is able to produce large volumes with a high level of consistency. The facility is capable of producing a full range of CBD extracts and isolates. The MJT production facility is focussed on product development for MYM owned brands and white label production of a range of brands looking to enter the CBD sphere. MYM owns 100% of MJT. DR. FURBABY ($) 80, ,000 1,280,000 2,560,000 TOTAL SALES ($) 480,000 4,320,000 9,280,000 18,560,000 PROJECTED GROWTH OF MYM S CBD BRANDS MYM currently selling the HempMed brand across Canada in over 90 stores and will be launching the Joshua Tree brand in Canada and the USA in Q HempMed is targeted at dispensary consumers and the Joshua Tree line is our mainstream brand for drug stores. MYM has two distributors on board in the USA as soon as the line is ready for launch. Dr. Furbaby, our line of CBD products for pets, will also launch alongside Joshua Tree in drug stores and dispensaries in Canada and the USA. $40 MILLION $30 MILLION $20 MILLION $10 MILLION $0

12 The MYM Team ERICK FACTOR, EXECUTIVE CHAIRMAN Mr. Erick Factor has been appointed to the Company s Board of Directors and will also serve as Executive Chairman. Mr. Factor is a well-known expert in the cannabis industry and has 20 years of experience in cultivating medical marijuana and manufacturing cannabis by-products. He has provided medical marijuana to thousands of patients over the past two decades. Mr. Factor is also the founder of the Westcoast Medicann dispensary, one of just a handful of dispensaries in Vancouver to be licensed under the City of Vancouver s stringent bylaws. He has extensive experience working with Health Canada, from whom he has obtained MMAR and MMPR licenses for hundreds of patients, and has managed and operated grow facilities to produce for those patients. Mr. Factor has also gained invaluable experience over the past three years in ACMPR licensing regulations and applications. ROB GIETL, CEO Mr. Gietl was most recently the Director of Business Development at NRI Global Inc. where he headed up multi-million dollar industrial acquisitions, environmental remediation and global sales of reusable assets and commodities. His skills in negotiations and plan development enabled him to leverage partnerships to accelerate expansion and facilitate synergy in execution. Mr. Gietl is well known for his ability to exponentially grow businesses including the west coast franchise expansion of Dominos Pizza, where he Consistently grew the annual business to achieve 300+% increases year over year. Mr. Gietl is a seasoned Business Development and Operations executive with a diverse track record of leading change across all areas of concept creation, brand re-positioning, market penetration, fiscal accountability and efficient execution of business plans. He has grown business effectiveness in an array of sectors and circumstances throughout Canada, consistently aligned with stakeholders goals and values. IAN RAMAGE, DIRECTOR Ian Ramage grew up in British Columbia and holds a Computer Engineering degree from Simon Fraser University and J.D. and LL.M. degrees from the University of British Columbia. He practiced law in the Bay Area for eight years for a variety of biotech and high-tech clients, returning to Vancouver in 2009 to continue to build his corporate and securities practice. Most recently, Ian was counsel for a national chain of marijuana dispensaries and has advised several others on marijuana regulations and corporate matters. MARK FORSTER, CFO Mark Forster will be responsible for the preparation of financial statements, continuing disclosure of the Resulting Issuer and the management of internal control procedures. He has over 25 years of financial accounting experience in banking, manufacturing of beer, wine, and spirits, the oil and gas industry and in the mining sector. He has been a director and the CFO of Teletouch Services Inc., a private technology company, since December He was a manager of BearingPoint LLP, a management and technology company, from January 1996 to December Mark G. Forster was granted a CGA designation by the Certified General Accountant s Association, BC in JONATHAN FITENI, OPERATIONS MANAGER Jonathan Fiteni has over 14 years of experience in the medical cannabis industry in general, and in product development and construction of marijuana facilities in particular. Mr. Fiteni is very educated and experienced in producing medical quality cannabis strains from seed to patient. He has designed and managed the building of numerous high-density growing facilities, requiring stringent construction standards. Using hydroponics and other sophisticated growing methods, he has successfully integrated complex electrical, dehumidification, HVAC and irrigation systems together to produce high quality organic marijuana products.

13 CONFIDENTIALITY STATEMENT AND LEGAL DISCLAIMER This Business Plan is confidential. Unauthorized reproduction or distribution of it or any of its contents in any form or under any circumstances without prior written consent is prohibited. The Recipient is responsible for returning all copies of the Plan immediately upon request of the Company. The information contained herein is: (i) provided by the principal founders of the business and (ii) publicly available from directories, publications, and websites, as mentioned in the body and the footnotes where possible or appropriate. In some cases, non-publicly available information was used, including independent research, studies or paid services from individuals and organizations. While the information set forth herein is deemed by the Company to be accurate, the Company shall not be held liable for the accuracy of or any omissions from this Business Plan or for any other written or oral communication transmitted to the Recipient and any other party in the course of its evaluation of transactions involving the Company. The information contained in the plan will require careful scrutiny, verification and due diligence efforts from the Recipients of the plan. Any person or entity seeking to make an investment in the business should not rely on the information set forth in the plan as complete. In addition, the analyses contained herein do not claim to be appraisals of the assets or the valuation of any entity. The business makes no guarantees regarding any benefits received from an investment, nor the legal, tax or accounting effects of any transaction; and this Plan does not constitute an offer to sell, or a solicitation of an offer to buy securities. In furnishing the Business Plan, the Company undertakes no obligation to provide Recipients of the Business Plan with access to any additional information or to update this Business Plan or to correct any inaccuracies that may be contained herein. There exists substantial information with respect to the business and its future prospects, and there are a substantial number of risks associated with an investment in the business, which are not set forth in the plan. Furthermore, the potential fulfillment of forward looking statements contained in the plan are subject to change due to unexpected events, market shifts, or circumstances that cannot be known at this time. Forward looking statements are based on expectations, estimates and projections at the time the statements were made that involve a number of economic, business, and numerous risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in the plan may be identified through the use of words such as, but not exclusively to: expects, will, anticipates, estimates, believes, or statements indicating certain actions may, could, or might occur. Such estimates and projections are subject to significant uncertainties beyond the control of the Company. Although such projections are believed to be realistic, no representations are made as to their ultimate attainability.